Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents.
Antidepressants produce various immunomodulatory effects, as well as an attenuation of the behavioral responses to immune challenges, such as lipopolysaccharide (LPS). To explore further the effects of antidepressants on neuroimmune interactions, rats were treated daily with either fluoxetine (Prozac) or saline for 5 weeks, and various behavioral, neuroendocrine, and immune functions were measured following administration of either LPS or saline. Chronic fluoxetine treatment significantly attenuated the anorexia and body weight loss, as well as the depletion of CRH-41 from the median eminence and the elevation in serum corticosterone levels induced by LPS. Chronic treatment with imipramine also attenuated LPS-induced adrenocortical activation. In rats and in mice, which normally display a biphasic body temperature response to LPS (initial hypothermia followed by hyperthermia), chronic treatment with fluoxetine completely abolished the hypothermic response and facilitated and strengthened the hyperthermic response. The effects of antidepressants on the responsiveness to LPS are probably not mediated by their effects on peripheral proinflammatory cytokine production, because LPS-induced expression of TNFalpha and IL-1beta mRNA in the spleen (assessed by semiquantitative in situ hybridization) was not altered following chronic treatment with either fluoxetine or imipramine. The effects of antidepressants on the acute phase response may have important clinical implications for the psychiatric and neuroendocrine disturbances that are commonly associated with various medical conditions.
Yirmiya
R
R
Department of Psychology, The Hebrew University of Jerusalem, Mount Scopus, Jerusalem, Israel.
Pollak
Y
Y
Barak
O
O
Avitsur
R
R
Ovadia
H
H
Bette
M
M
Weihe
E
E
Weidenfeld
J
J
D000311:Adrenal Glands / Q000187:drug effects / Q000378:metabolism; D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects* / Q000502:physiology; D001831:Body Temperature / Q000187:drug effects / Q000502:physiology; D001921:Brain / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D003345:Corticosterone / Q000378:metabolism; D016207:Cytokines / Q000235:genetics; D004334:Drug Administration Schedule / Q000662:veterinary; D004347:Drug Interactions / Q000502:physiology; D005473:Fluoxetine / Q000494:pharmacology; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects / Q000378:metabolism; D007099:Imipramine / Q000494:pharmacology; D007107:Immune System / Q000187:drug effects* / Q000502:physiology; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008297:Male; D015213:Neuroimmunomodulation / Q000187:drug effects* / Q000502:physiology; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D011916:Rats, Inbred F344; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D013154:Spleen / Q000187:drug effects / Q000378:metabolism
D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D003345:Corticosterone; D016207:Cytokines; D005473:Fluoxetine; D007099:Imipramine; D008070:Lipopolysaccharides; D012333:RNA, Messenger; D017367:Selective Serotonin Reuptake Inhibitors